Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson's disease model. Academic Article uri icon

Overview

abstract

  • Neurophysiological studies of the brain in normal and Parkinson's disease (PD) patients have indicated intricate connections for basal ganglia-induced control of signaling into the motor cortex. To investigate if similar mechanisms are controlling function in the primate brain (Macaca fascicularis) after MPTP-induced neurotoxicity, we conducted PET studies of cerebral blood flow, oxygen and glucose metabolism, dopamine transporter, and D2 receptor function. Our observations after MPTP-induced dopamine terminal degeneration of the caudate and putamen revealed increased blood flow (15%) in the globus pallidus (GP), while blood flow was moderately decreased (15-25%) in the caudate, putamen, and thalamus and 40 % in the primary motor cortex (PMC). Oxygen extraction fraction was moderately increased (10-20%) in other brain areas but the thalamus, where no change was observable. Oxygen metabolism was increased in the GP and SMA (supplementary motor area including premotor cortex, Fig. 3) by a range of 20-40% and decreased in the putamen and caudate and in the PMC. Glucose metabolism was decreased in the caudate, putamen, thalamus, and PMC (range 35-50%) and enhanced in the GP by 15%. No change was observed in the SMA. In the parkinsonian primate, [(11)C]CFT (2beta-carbomethoxy-3beta-(4-fluorophenyltropane) dopamine transporter binding was significantly decreased in the putamen and caudate (range 60-65%). [(11)C]Raclopride binding of dopamine D(2) receptors did not show any significant changes. These experimental results obtained in primate studies of striato-thalamo-cortico circuitry show a similar trend as hypothetized in Parkinson's disease-type degeneration.

publication date

  • October 1, 2003

Research

keywords

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Brain
  • Brain Mapping
  • Dopamine Agents
  • Membrane Glycoproteins
  • Nerve Tissue Proteins
  • Parkinson Disease, Secondary

Identity

Scopus Document Identifier

  • 0142074677

Digital Object Identifier (DOI)

  • 10.1016/S1053-8119(03)00348-3

PubMed ID

  • 14568476

Additional Document Info

volume

  • 20

issue

  • 2